Key Transaction Details

  • The company has decided to close the manufacturing operations of its drug intermediates manufacturing unit located at Plot Nos. C-89 to C-95, MIDC, Mahad 402309, Maharashtra.
  • The leasehold land (admeasuring approximately 25,138 sq mtrs) along with old factory buildings, structures, and sheds (admeasuring approximately 11,913 sq mtrs) standing on it will be sold/transferred to M/s. ICMC Corporation Ltd.
  • The consideration for the sale/transfer of leasehold rights on the land along with the structures is ₹16.90 crores.

Operational and Financial Impact

  • The drug intermediates manufactured at this unit have already been transferred to other manufacturing units of the company. The plant and machinery from this unit will also be transferred to other company units.
  • The closure and sale will not have any impact on the company's business and financials.
  • The manufacturing unit was primarily producing drug intermediates for captive use in the company's API manufacturing. The current written down value of the leasehold land and buildings/structures is ₹13.21 crores.

Transaction Timeline and Approvals

  • A Memorandum of Understanding (MOU) was entered into with the buyer on November 20, 2026.
  • The final transaction deed will be executed subject to necessary approvals and consents, primarily from MIDC for the transfer of leasehold rights.
  • The expected date of completion is on or before March 31, 2027, or another mutually agreed date.

Counterparty Information

  • The buyer, M/s. ICMC Corporation Ltd., is a company incorporated under the Companies Act, 1956, engaged in the development, manufacture, distribution, and sale of micro nutrients fertilizers.
  • ICMC Corporation Ltd. does not belong to the promoter/promoter group of Ipca Laboratories and is not a related party. The transaction does not fall under related party transactions and is being done at arm's length.

Rationale

The decision is part of the company's ongoing initiative to optimize manufacturing facilities and reduce the number of smaller manufacturing units to minimize operational and other costs.

Capital Structure Impact

There will be no change in the shareholding pattern of the company due to this transaction.